Literature DB >> 3580264

Photodynamic therapy with phthalocyanine sensitisation: quantitative studies in a transplantable rat fibrosarcoma.

C J Tralau, A J MacRobert, P D Coleridge-Smith, H Barr, S G Bown.   

Abstract

Photodynamic therapy (PDT) is a promising approach to the local destruction of malignant tumours, but little work has been done to determine which factors control the extent of tissue necrosis produced. Using a new photosensitiser, a sulphonated aluminium phthalocyanine (AlSPc) and light from an argon ion pumped dye laser at 675 nm, we quantified the effects of interstitial PDT in a transplantable fibrosarcoma in rats. At 100mW laser power, thermal effects were comparable to those of PDT, so subsequent studies were carried out at 50 mW, where thermal effects were minimal. The depth of PDT necrosis increased with the logarithm of the applied energy. Tissue concentration of AlSPc was measured by alkali extraction and at all times after sensitisation, correlated well with the necrosis produced with a given light dose. Peak tumour concentration of AlSPc occurred 24-48 h after sensitisation compared with a peak at 3 h in muscle. The peak ratio tumour:muscle was 2:1 at 24 h. Apart from a different time interval to reach the peak sensitiser concentration, the extent of tumour damage varied with the light and sensitiser parameters in a similar way to that found in normal liver, although the optical penetration depth was greater in the tumour (2.5 mm vs. 1.8 mm). At doses of AlSPc below 1 mg kg-1 the diameter of necrosis increased with the logarithm of the dose of sensitiser, and doubling the dose from 0.25 to 0.5 mg kg-1 increased the depth of necrosis by 50%. However, at higher doses, the changes were smaller and increasing the dose from 2.5 to 5 mg kg-1 only increased the necrosis by 10% for the same light dose. In all dose ranges, a given percentage increase in the tissue concentration of AlSPc gave a much smaller percentage increase in the extent of necrosis for the same light dose, suggesting that selectivity of necrosis between tumour and normal tissue is likely to be much less than the selectivity of retention of the photosensitiser. From these results, the extent of PDT necrosis in this fibrosarcoma is as predictable as it is in normal liver if the light dose, tissue concentration of AlSPc and optical penetration depth of the tissue are known. Further studies are now required on different tumour models to establish how tumours respond compared with adjacent normal tissue when the tumour is growing in its organ of origin rather than the non-physiological situation using a transplantable tumour as in this study.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580264      PMCID: PMC2001712          DOI: 10.1038/bjc.1987.78

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Hematoporphyrin-derivative fluorescence in malignant neoplasms.

Authors:  H B Gregorie; E O Horger; J L Ward; J F Green; T Richards; H C Robertson; T B Stevenson
Journal:  Ann Surg       Date:  1968-06       Impact factor: 12.969

2.  Optical properties of human brain.

Authors:  L O Svaasand; R Ellingsen
Journal:  Photochem Photobiol       Date:  1983-09       Impact factor: 3.421

3.  Dosimetry considerations in phototherapy.

Authors:  A E Profio; D R Doiron
Journal:  Med Phys       Date:  1981 Mar-Apr       Impact factor: 4.071

4.  Synthesis, tissue distribution and tumor uptake of [99Tc]tetrasulfophthalocyanine.

Authors:  J Rousseau; D Autenrieth; J E van Lier
Journal:  Int J Appl Radiat Isot       Date:  1983-03

5.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue.

Authors:  C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

6.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor.

Authors:  K R Weishaupt; C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

7.  Hematoporphyrin derivative: quantitative uptake in dimethylhydrazine-induced murine colorectal carcinoma.

Authors:  M V Agrez; R E Wharen; R E Anderson; E R Laws; D M Ilstrup; D A Cortese; R G Shorter; M M Lieber
Journal:  J Surg Oncol       Date:  1983-11       Impact factor: 3.454

8.  Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates.

Authors:  D Mew; C K Wat; G H Towers; J G Levy
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

9.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse.

Authors:  P J Bugelski; C W Porter; T J Dougherty
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo.

Authors:  G Jori; M Beltramini; E Reddi; B Salvato; A Pagnan; L Ziron; L Tomio; T Tsanov
Journal:  Cancer Lett       Date:  1984-10       Impact factor: 8.679

View more
  7 in total

1.  Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas.

Authors:  S G Smith; J Bedwell; A J MacRobert; M H Griffiths; S G Bown; M R Hetzel
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 2.  Photodynamic therapy for colorectal disease.

Authors:  H Barr; S G Bown; N Krasner; P B Boulos
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

Review 3.  Like a bolt from the blue: phthalocyanines in biomedical optics.

Authors:  Nawal Sekkat; Hubert van den Bergh; Tebello Nyokong; Norbert Lange
Journal:  Molecules       Date:  2011-12-23       Impact factor: 4.411

4.  Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency.

Authors:  E Reddi; C Zhou; R Biolo; E Menegaldo; G Jori
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

5.  Photocytotoxic efficacy of sulphonated species of aluminium phthalocyanine against cell monolayers, multicellular spheroids and in vivo tumours.

Authors:  W S Chan; C M West; J V Moore; I R Hart
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

6.  Pharmacokinetic studies with zinc(II)-phthalocyanine in tumour-bearing mice.

Authors:  E Reddi; G Lo Castro; R Biolo; G Jori
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

7.  Photodynamic therapy in the normal rat colon with phthalocyanine sensitisation.

Authors:  H Barr; C J Tralau; A J MacRobert; N Krasner; P B Boulos; C G Clark; S G Bown
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.